Award from Bechtel includes supply of the primary liquefaction equipment for NextDecade’s Rio Grande LNG Train 5Order includes Frame 7 gas turbines and centrifugal compressors, replicating proven solutions from previous trainsTechnology will enable an additional LNG production capacity of approximately 6 MTPA HOUSTON and LONDON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Baker Hughes (NASDAQ: BKR), an energy technology company, announced Thursday an award from engineering company Bechtel Energy Inc. (Bechtel) to sup ...

Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway to approval of OPGx-LCA5First participant enrolled in run-in period for planned adaptive Phase 3 trialCompany intends to apply for the FDA’s new Rare Disease Evidence Principles (RDEP) review processOPGx-LCA5 has the potential to be the first gene therapy and one-time treatment for Leber congenital amaurosis (LCA) type 5Recent $23 million financing led by Perceptive Advisors and Baly ...

- Record Quarterly Revenue of $260.5 Million, Up 9.3% Year-Over-Year Led by 7.6% Organic Growth - - Single-Family Residential Business and Multi-Family/Commercial Business Each Achieved Record Quarterly Revenues Through Market Share Gains and Geographic Expansion - - Net Income of $47.2 Million, or $1.01 Per Diluted Share, Marking the Second Most Profitable Quarter in the History of the Company - - Adjusted Net Income1 of $46.7 Million, or $1.00 Per Diluted Share - - Adjusted EBITDA1 of $79.1 Million, Repre ...

Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline results expected in the first half of 2027Strong balance sheet, bolstered by approximately $269.4 million in net proceeds from recent public offering Ended the quarter with $513.0 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations into ...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced seven presentations at the American Society of Nephrology’s (ASN) Kidney Week, being held November 6-9 in Houston, Texas. During the meetings, Maze Therapeutics will present additional pharmacokinetic data from its Phase 1 clinical trial of MZE782, as wel ...

- Financing led by Perceptive Advisors and Balyasny Asset Management - - Proceeds targeted to fund rapid development of ophthalmic gene therapy clinical programs - RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”) a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that it has en ...

Call Scheduled for November 13th at 1:00 PM ET SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its equipment leasing and direct patient care services segments, today announced that the Company will hold a conference call to discuss its third quarter 2025 financial results on November 13th at 1:00 pm ET. The third q ...

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected by end of year Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected by end of year Approximately $145.1 million cash, cash equivalents and restricted cash as of September 30, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA tria ...

SANTA CLARA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Agora, Inc. (NASDAQ: API), a pioneer and leader in conversational AI and real-time engagement technology, will release its financial results for the third quarter ended September 30, 2025 after the close of U.S. markets on November 19, 2025. Agora, Inc. will host a conference call to discuss the financial results at 5 p.m. Pacific Time / 8 p.m. Eastern Time on the same day. Details for the conference call are as follows: Event title: Agora, Inc. 3Q 2025 ...

MIDDLETOWN, R.I., Nov. 06, 2025 (GLOBE NEWSWIRE) -- KVH Industries, Inc. (Nasdaq: KVHI), reported financial results for the quarter ended September 30, 2025 today. The company will hold a conference call to discuss these results at 9:00 a.m. ET today, which can be accessed at investors.kvh.com. Following the call, a replay of the webcast will be available through the company’s website. Third Quarter 2025 Highlights Total revenues in the third quarter of 2025 increased sequentially from the second quarter of ...